

## Altman Clinical and Translational Research Institute

## Combined Executive Committee and Leadership Cabinet Meeting Minutes March 18, 2025

**Present:** Davey Smith, Colin Depp, Kathryn Gold, Mark Wallace, Mike Hogarth, Liz Johnson,

Adriana Tremoulet, Borsika Rabin, Eric Mah, Sam Ward, Stephanie Farrell, Raul Lizarraga, Jamison

Langguth

**Absent:** Murray Stein, John Ayers, David Boyle, Christina Chambers, Paul Watson

Guests: Carlos Rojas, Su-Yin Chang, Karole Ignacio, Len Lazaro, Maryam Gholami, Gretchen Bandoli,

Blanca Melendrez

**Recorder:** Nancy Giordanengo

Agenda Item	Notes	Action Items, Comments
Call to Order	Davey Smith called the meeting to order at 2:30pm	
Opening remarks & welcome new members (Davey)	<ul> <li>Welcome new Leadership Cabinet members:         <ul> <li>Borsika Rabin, PhD, MPH, PharmD</li> <li>Adriana Tremoulet, MD, MAS</li> </ul> </li> <li>Welcome new Executive Committee members:         <ul> <li>Jamison Langguth, MPH, MSED</li> <li>Director of Clinical Research Sanford Stem Cell Clinical Center, UC San Diego CIRM Alpha Clinic</li> </ul> </li> <li>Raul A. Lizarraga Jr, BSN, RN         <ul> <li>Clinical Research Lead, El Centro Regional Medical Center</li> </ul> </li> <li>Stephanie Farrell, MBA, RN, CCRC, OCN         <ul> <li>Director of Research, Eisenhower Health</li> </ul> </li> </ul>	
Congratulations (Davey)	Congratulations to Sam Ward who was appointed Vice Dean for Research at the School of Medicine.	
Presentation: KL2, SUSTAIN and K12, SUSTAIN, UL1 (Adri & Colin)	<ul> <li>KL2:</li> <li>Highlights from 2010-2024:</li> <li>36 scholars completed</li> <li>Total publications = 1588 [mean=58 (sd=42) per scholar]</li> <li>96% have remained in research</li> <li>66% have been awarded an R01 or equivalent</li> <li>Current projects and scholars overview:</li> <li>Eight new scholars</li> </ul>	
	SUSTAIN:  • Institutionally funded program for URM faculty in transition from K to independence or for KL2 applicants	

	who are not selected. Current scholar's project ends May 2, 2025  UL1 Diversity Supplement Award:  • Awarded 2-year NARSAD early investigator award 5/21/23-4/30/25  K12/SUSTAIN program current status:  • K12 submission received positive score (impact: 21) but awaiting council and requires linked U award funding  • Submitted NCE and will submit CE request for bridge scholars  • RFAs for new scholars for either SUSAIN or K12 cancelled until further notice  Challenges:  • Gap funding, SUSTAIN concept, changes in eliminating diversity focus  Opportunity:  • UCI created a workgroup for strategies that K awardees should know when using Al in research and career development.  We are collecting ideas of applications, tools, thoughts. In the future we can put together a course or workshop.	
Update on the status of the CTSA re-review and resubmission (Davey)	The CTSA re-review for our primary application is April 21. If greater than 34 we will withdraw the application and resubmit a new application for the May deadline. If it scores in the middle we will respond to summary statement with a resubmission for the September deadline. We are keeping an eye on the progress of the University of Utah CTSA grant.	
Update on the status of the KL1 and UL1 cost extension requests (Davey)	<ul> <li>Status of cost extension requests:</li> <li>Submitting cost extension requests for both the UL1 and KL2</li> <li>Requesting 50% of annual budgets</li> <li>Will submit no later than March 26 (institutional review slated for March 13)</li> </ul>	
Center for Clinical Research updates (Mark)	<ul> <li>Center for Clinical Research (CCR) – ACTRI@LindaVista:</li> <li>Clinic is fully operational; construction projects wrapped on Feb 25</li> <li>Feb 26 open house welcomed 63 attendees and included remarks from leadership included VCHS Carethers, Dr. Davey Smith, Dr. Gary Firestein, and Dr. Gaby Haddad</li> <li>Issued follow-up emails to investigators who expressed interest in using the clinic</li> <li>Working with Finance team for a time-limited reduced study set up fee to incentivize investigators.</li> </ul>	PEDS space at 7910 Frost: Adri will help get the word out to PEDs to let them know about the space.

	CCR L2 Clinic – details & timeline: The original clinic is 18,000 sqft. The additional space is an additional 3,500 sqft. It will have everything that the original clinic has:  • Start of construction: July/August 2024  • Planned substantial construction completion: April 7, 2025  • Planned move-In: April/May 2025  CCR – Hillcrest Multipurpose Clinical Research Building:  • On hold. Disruptions in federal funding have impacted all capital projects related to research  • Leadership is exploring contingency plans now and will have more to share soon  • Working on alternative locations until this can move forward	
Update on the launch of the ACTRI CAB 2.0 (Borsika)	In preparation for the next grant submission/revision, major changes have been made on how we are convening with the CAB and general processes on how we engage with them:  • Clearer integration of community priorities into research  → Not just feedback but shared decision-making  • Emphasis on research-to-policy translation → Using research for systemic change and advocacy  • Expanding representation across diverse sectors for greater impact →  ○ County HHSA  ○ Community-Based Organizations  ○ BIPOC representatives  ○ Healthcare Leaders  ○ Policy Advocates  ○ Community Members with Lived Experience  Next steps:  • CAB Kickoff Meeting (Early April 2025): Onboarding, priority-setting, and research-community engagement strategy  • CAB Networking Event (April/May 2025): Strengthening partnerships, fostering collaboration, and aligning shared goals	
BMI & MCC Updates (Mike)	Moores Cancer Center (MCC) Clinical Trials Office (CT) wants to implement OnCore as their clinical trial management system (CTMS), instead of using Velos:  • There have been several meetings between health sciences leadership and MCC leadership on this issue, including a recent meeting in which the cost estimation by MCC was \$12 million (HS IS estimated \$20 million)  • MCC and the Vice Chancellor are in continued discussions	

	<ul> <li>MCC outlined 6 items they desire in a CTMS and they are evaluating Velos 13 for those and they will complete the assessment ~May</li> <li>ACTRI has underwritten the MCC's use of Epic Research and Velos for 3 years. Starting Feb 1, 2025, MCC CTO is being recharged for prospective effort</li> </ul>
March 4 Listening Session debrief (Liz)	<ul> <li>79 attendees via Zoom; 11 in person</li> <li>Featured updates and insights from SOM leadership (Dean Barbara Jung and Vice Dean for Research Sam Ward) on actions taken to date</li> <li>A modified version of the SOM leadership slides was shared, along with wellness resources</li> <li>Liz &amp; Jen held office hours following to accommodate 1:1 requests</li> <li>A town hall for staff scheduled for April 23 – will feature another update from leadership about executive orders/policy changes as well as CTSA grant updates</li> </ul>
Next meeting: May 20	